ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?
Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency's CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch.
See our latest analysis for Neuren Pharmaceuticals.
That CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline...

